Indian pharma firms focus on specialty drugs amid ongoing generic pricing pressure.
FMCG players are shifting to margin-driven strategies; food segment seen growing in double digits.
Cement and hotel sectors show strong performance; auto outlook remains selectively positive.
Despite US exposure, Indian pharma doesn’t face major structural negatives, says Pankaj Pandey.
Comments
Post a Comment